View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 20, 2022

Paragraf plans to develop graphene-based in-vitro diagnostic products

Paragraf will develop a proof-of-concept combined PCT and CRP test that will differentiate between bacterial and other infections.

Cambridgeshire-based Paragraf has announced plans to develop a new generation of graphene-based, in-vitro diagnostic products that will provide results in a few minutes.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The company is commencing a two-year programme to develop a proof-of-concept combined PCT (procalcitonin) and CRP (C-reactive protein) test that can differentiate between bacterial and other infections.

For the project, Paragraf is partnering with the Universities of Liverpool, Manchester and Newcastle, as well as the Manchester University NHS Foundation Trust (MFT) and Newcastle upon Tyne Hospitals NHS Foundation Trust.

Slated to be completed by the end of May 2024, the collaborative project will leverage a $659,472 (£550,000) Biomedical Catalyst grant obtained from Innovate UK, an innovation agency.

A clinical study of the combined PCT/CRP test is planned to be delivered in mid-2023 at MFT’s Diagnostics and Technology Accelerator (DiTA), which aims to address unmet needs, improve efficiency and transform patient care in the NHS with the quick conversion and adoption of new inventions.

Paragraf diagnostics business development director Malcolm Stewart said: “This graphene-based diagnostic test is expected to become the first test in the world to give clinicians the ability to identify patients who need an antibiotic treatment within the space of a regular 15-minute clinic appointment.

“It encourages antimicrobial stewardship by giving clinicians the insight into when not to prescribe antibiotics as the test result differentiates viral from bacterial infections.

“The ambition is to develop a comprehensive suite of tests that could be used in almost any environment or healthcare setting.”

In March, the company raised funds of $60m in a Series B financing round.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network